We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+29.29%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$9.47B
AUM Growth
+$451M
Cap. Flow
+$1.13B
Cap. Flow %
11.96%
Top 10 Hldgs %
21.59%
Holding
903
New
107
Increased
255
Reduced
393
Closed
103

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$51.9M
2
MRK icon
Merck
MRK
+$50.9M
3
DHR icon
Danaher
DHR
+$45.3M
4
TMO icon
Thermo Fisher Scientific
TMO
+$37.8M
5
JD icon
JD.com
JD
+$37.7M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$103M
2
BABA icon
Alibaba
BABA
+$98.6M
3
CRM icon
Salesforce
CRM
+$62.5M
4
BMY icon
Bristol-Myers Squibb
BMY
+$59.4M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$48.6M

Sector Composition

Rank Sector Weight
1 Healthcare 34.61%
2 Technology 20.94%
3 Consumer Discretionary 8.9%
4 Financials 8.59%
5 Communication Services 7.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
126
Neurocrine Biosciences
NBIX
$17.7B
$19.1M 0.2%
156,282
-30,484
-16% -$3.37M
BALL icon
127
Ball Corp
BALL
$17.2B
$18.9M 0.2%
271,761
+152,954
+129% +$10.3M
HRTX icon
128
Heron Therapeutics
HRTX
$86.9M
$18.8M 0.2%
1,278,972
+578,462
+83% +$9.5M
MRNA icon
129
Moderna
MRNA
$22.1B
$18.6M 0.2%
+285,834
New +$15.7M
XYL icon
130
Xylem
XYL
$28.6B
$18.1M 0.19%
278,827
-246,681
-47% -$16.3M
AMT icon
131
American Tower
AMT
$77.7B
$17.9M 0.19%
69,411
+18,393
+36% +$4.55M
MAS icon
132
Masco
MAS
$16.4B
$17.8M 0.19%
354,109
+249,610
+239% +$10.8M
INTU icon
133
Intuit
INTU
$83.1B
$17.7M 0.19%
59,868
-10,345
-15% -$2.84M
SQM icon
134
Sociedad Química y Minera de Chile
SQM
$19.6B
$17.5M 0.18%
+670,400
New +$16.1M
SNPS icon
135
Synopsys
SNPS
$74.5B
$17.5M 0.18%
89,560
+25,906
+41% +$4.28M
NEO icon
136
NeoGenomics
NEO
$1.71B
$17.4M 0.18%
562,098
+95,433
+20% +$2.64M
XP icon
137
XP
XP
$8.65B
$17.4M 0.18%
413,000
+289,000
+233% +$8.87M
SLAB icon
138
Silicon Laboratories
SLAB
$7.17B
$17.2M 0.18%
171,480
+59,947
+54% +$5.6M
MS icon
139
Morgan Stanley
MS
$337B
$17.2M 0.18%
355,280
+43,937
+14% +$1.85M
IBKC
140
DELISTED
IBERIABANK Corp
IBKC
$17M 0.18%
374,285
+265,246
+243% +$11M
TRMB icon
141
Trimble
TRMB
$13B
$16.9M 0.18%
391,903
-134,655
-26% -$5.05M
MEET
142
DELISTED
The Meet Group, Inc. Common Stock
MEET
$16.7M 0.18%
+2,677,137
New +$16.5M
AKBA icon
143
Akebia Therapeutics
AKBA
$343M
$16.7M 0.18%
+1,229,346
New +$12.7M
HUM icon
144
Humana
HUM
$45.8B
$16.6M 0.18%
42,805
+3,122
+8% +$1.17M
AZTA icon
145
Azenta
AZTA
$1.27B
$16.6M 0.18%
374,787
+60,741
+19% +$2.32M
EXAS
146
DELISTED
Exact Sciences
EXAS
$16.3M 0.17%
187,928
+71,571
+62% +$5.72M
CBRE icon
147
CBRE Group
CBRE
$42.1B
$16.3M 0.17%
359,831
-31,912
-8% -$1.38M
NEM icon
148
Newmont
NEM
$98.5B
$16.3M 0.17%
263,291
-105,096
-29% -$6.22M
AMD icon
149
Advanced Micro Devices
AMD
$807B
$15.9M 0.17%
302,722
-77,836
-20% -$4.13M
IBM icon
150
IBM
IBM
$204B
$15.9M 0.17%
137,797
-10,493
-7% -$1.22M
4 5
6
7 8

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q2 2020 Portfolio in Review

As of Q2 2020, Candriam SCA held 903 positions worth $9.47B, up 5% from $9.02B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Candriam SCA deployed $1.13B of net new capital in Q2 2020, opening 107 new positions and adding to 255 existing holdings. Its largest new stake was JD.com: 744,410 shares worth $44.8M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 31% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $103M trimmed.

  • Candriam SCA's largest Q2 2020 buy was JD.com: 744,410 shares worth $44.8M.
  • Candriam SCA added most to Blueprint Medicines in Q2 2020, an estimated $51.9M increase.
  • Candriam SCA's biggest Q2 2020 reduction was Regeneron Pharmaceuticals, cutting an estimated $103M.
  • Candriam SCA fully exited Salesforce in Q2 2020, selling an estimated $62.5M.
  • Candriam SCA's ten largest holdings make up 22% of its $9.47B portfolio in Q2 2020.
  • Candriam SCA opened 107 new positions and closed 103 in Q2 2020.
  • Candriam SCA's portfolio value rose 5% quarter-over-quarter to $9.47B.

Based on Candriam SCA's 13F filing for Q2 2020, filed 23 Jul 2020.